Showing 7,821 - 7,840 results of 18,874 for search '(( significant a decrease ) OR ( significant ((changes decrease) OR (larger decrease)) ))', query time: 0.91s Refine Results
  1. 7821
  2. 7822

    Presentation 1_A phase 2a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of NuGel, a novel topical GPCR19-mediated inflammasome inhi... by Gyeong Ho Baek (21382907)

    Published 2025
    “…</p>Results<p>NuGel (0.3% [Nu0.3] and 0.5% [Nu0.5]) was well-tolerated, with no adverse drug reactions or serious adverse events. Nu0.3 showed a significant decrease in EASI score from baseline (-12.2%, [-30.3%, 5.9%], p = 0.04). …”
  3. 7823

    Presentation 3_A phase 2a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of NuGel, a novel topical GPCR19-mediated inflammasome inhi... by Gyeong Ho Baek (21382907)

    Published 2025
    “…</p>Results<p>NuGel (0.3% [Nu0.3] and 0.5% [Nu0.5]) was well-tolerated, with no adverse drug reactions or serious adverse events. Nu0.3 showed a significant decrease in EASI score from baseline (-12.2%, [-30.3%, 5.9%], p = 0.04). …”
  4. 7824

    Data Sheet 1_A phase 2a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of NuGel, a novel topical GPCR19-mediated inflammasome inhibi... by Gyeong Ho Baek (21382907)

    Published 2025
    “…</p>Results<p>NuGel (0.3% [Nu0.3] and 0.5% [Nu0.5]) was well-tolerated, with no adverse drug reactions or serious adverse events. Nu0.3 showed a significant decrease in EASI score from baseline (-12.2%, [-30.3%, 5.9%], p = 0.04). …”
  5. 7825

    Data Sheet 2_A phase 2a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of NuGel, a novel topical GPCR19-mediated inflammasome inhibi... by Gyeong Ho Baek (21382907)

    Published 2025
    “…</p>Results<p>NuGel (0.3% [Nu0.3] and 0.5% [Nu0.5]) was well-tolerated, with no adverse drug reactions or serious adverse events. Nu0.3 showed a significant decrease in EASI score from baseline (-12.2%, [-30.3%, 5.9%], p = 0.04). …”
  6. 7826

    Presentation 2_A phase 2a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of NuGel, a novel topical GPCR19-mediated inflammasome inhi... by Gyeong Ho Baek (21382907)

    Published 2025
    “…</p>Results<p>NuGel (0.3% [Nu0.3] and 0.5% [Nu0.5]) was well-tolerated, with no adverse drug reactions or serious adverse events. Nu0.3 showed a significant decrease in EASI score from baseline (-12.2%, [-30.3%, 5.9%], p = 0.04). …”
  7. 7827

    MRI grading systems’ diagnostic accuracy for MD. by Neda Azarpey (20308334)

    Published 2024
    “…Adjusting the threshold to EH grade 2 results in a sensitivity increase to 92.1% (CI: 85.9–95.7) and a specificity decrease to 70.6% (CI: 64.5–76.1), with a DOR of 28.056 (CI: 14.917–52.770). …”
  8. 7828

    MRI-based cochlear hydrops grading and PLE in MD. by Neda Azarpey (20308334)

    Published 2024
    “…Adjusting the threshold to EH grade 2 results in a sensitivity increase to 92.1% (CI: 85.9–95.7) and a specificity decrease to 70.6% (CI: 64.5–76.1), with a DOR of 28.056 (CI: 14.917–52.770). …”
  9. 7829

    Cochlear hydrops classification in MRI systems. by Neda Azarpey (20308334)

    Published 2024
    “…Adjusting the threshold to EH grade 2 results in a sensitivity increase to 92.1% (CI: 85.9–95.7) and a specificity decrease to 70.6% (CI: 64.5–76.1), with a DOR of 28.056 (CI: 14.917–52.770). …”
  10. 7830

    Summary of subgroup analysis results. by Junyin Pan (20700411)

    Published 2025
    “…The results showed that dietary anthocyanins significantly improved various lipid and glycemic markers:</p><p>HDL-C: increased by 0.05 mmol/L (95% CI: 0.01 to 0.10, p = 0.026), LDL-C: decreased by 0.18 mmol/L (95% CI: -0.28 to -0.08, p = 0.000), Triglycerides (TGs): reduced by 0.11 mmol/L (95% CI: -0.20 to -0.02, p = 0.021), Total cholesterol (TC): lowered by 0.34 mmol/L (95% CI: -0.49 to -0.18, p = 0.000), Fasting blood glucose (FBG): reduced by 0.29 mmol/L (95% CI: -0.46 to -0.12, p = 0.001), Glycated hemoglobin (HbA1c): decreased by 0.43% (95% CI: -0.74 to -0.13, p = 0.005). …”
  11. 7831

    Original study data. by Junyin Pan (20700411)

    Published 2025
    “…The results showed that dietary anthocyanins significantly improved various lipid and glycemic markers:</p><p>HDL-C: increased by 0.05 mmol/L (95% CI: 0.01 to 0.10, p = 0.026), LDL-C: decreased by 0.18 mmol/L (95% CI: -0.28 to -0.08, p = 0.000), Triglycerides (TGs): reduced by 0.11 mmol/L (95% CI: -0.20 to -0.02, p = 0.021), Total cholesterol (TC): lowered by 0.34 mmol/L (95% CI: -0.49 to -0.18, p = 0.000), Fasting blood glucose (FBG): reduced by 0.29 mmol/L (95% CI: -0.46 to -0.12, p = 0.001), Glycated hemoglobin (HbA1c): decreased by 0.43% (95% CI: -0.74 to -0.13, p = 0.005). …”
  12. 7832

    S2 File - by Junyin Pan (20700411)

    Published 2025
    “…The results showed that dietary anthocyanins significantly improved various lipid and glycemic markers:</p><p>HDL-C: increased by 0.05 mmol/L (95% CI: 0.01 to 0.10, p = 0.026), LDL-C: decreased by 0.18 mmol/L (95% CI: -0.28 to -0.08, p = 0.000), Triglycerides (TGs): reduced by 0.11 mmol/L (95% CI: -0.20 to -0.02, p = 0.021), Total cholesterol (TC): lowered by 0.34 mmol/L (95% CI: -0.49 to -0.18, p = 0.000), Fasting blood glucose (FBG): reduced by 0.29 mmol/L (95% CI: -0.46 to -0.12, p = 0.001), Glycated hemoglobin (HbA1c): decreased by 0.43% (95% CI: -0.74 to -0.13, p = 0.005). …”
  13. 7833

    Sequences of primers used for qRT-PCR. by Shujuan Hu (22656045)

    Published 2025
    “…Notably, aerobic exercise significantly increased <i>FNDC5</i>/irisin expression (<i>P</i> < 0.05), and decreased NLRP3 and IL-18 levels (<i>P</i> < 0.01). …”
  14. 7834

    A typical cross signalized intersection. by Bin Zhao (276445)

    Published 2025
    “…Numerical experiments using actual survey data from Kunshan City yield several noteworthy findings: (1) An optimal moderate-sized time step exists for rolling optimization to minimize either the average delay time or total costs; specifically, an excessively small time step may increase vehicle average delay time or total costs; (2) The percentage of delay reduction achieved by our method, compared to Synchro software, reaches a maximum of approximately 70% when traffic demand is moderate and the initial state is low; and (3) The percentage reduction in average delay or total costs compared to Synchro initially increases and then decreases with rising traffic intensity.…”
  15. 7835
  16. 7836
  17. 7837
  18. 7838
  19. 7839
  20. 7840